Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.

PloS one - 1 Jan 2016

Park Hyung Soon, Lim Sun Min, Kim Sora, Kim Sangwoo, Kim Hye Ryun, Kwack KyuBum, Lee Min Goo, Kim Joo-Hang, Moon Yong Wha

Abstract excerpt

We evaluated the preliminary efficacy and feasibility of a next-generation sequencing (NGS)-based targeted anticancer therapy in refractory solid tumors at a Korean institution. Thirty-six patients with advanced cancer underwent molecular profiling with NGS with the intent of clinical application of available matched targeted agents. Formalin-fixed paraffin-embedded (FFPE) tumors were sequenced using the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Feasibility Studies

Share to Niacinamide

Share to Phenylurea Compounds

Share to Quinazolines

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 27105424
DOI: 10.1371/journal.pone.0154133
PMCID: PMC4841558

Genes

BRAF
ERBB2
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.PMID 27105424Read ↗

Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.Semantic proximity Read ↗

Pragmatic Nationwide Master Observational Trial Based on Genomic Alterations in Advanced Solid Tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II Study Protocol KCSG AL-22-09Semantic proximity Read ↗

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.Semantic proximity Read ↗

Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing PanelSemantic proximity Read ↗

Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study.Semantic proximity Read ↗

Targeted therapy according to next generation sequencing-based panel sequencingSemantic proximity Read ↗

A Pilot Study Using Next-Generation Sequencing in Advanced Cancers: Feasibility and ChallengesSemantic proximity Read ↗

Next-Generation Sequencing for Patients with Sarcoma: A Single Center ExperienceSemantic proximity Read ↗

Next-Generation Sequencing-Based Evaluation of the Actionable Mutational Landscape in Solid Tumors: the “MOZART” Prospective Observational StudySemantic proximity Read ↗

Expanding individualized therapeutic options via genoproteomics.Semantic proximity Read ↗

Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients.Semantic proximity Read ↗

New Era for Next-Generation Sequencing in JapanSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.